Johannes Ettl
Kempten University of Applied Sciences(DE)Klinikverbund Südwest(DE)München Klinik(DE)Technical University of Munich(DE)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, PARP inhibition in cancer therapy, BRCA gene mutations in cancer
Most-Cited Works
- → Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation(2018)2,082 cited
- → The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study(2014)1,891 cited
- → Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up(2019)426 cited
- → Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial(2020)376 cited
- → Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study(2021)370 cited